|Home | About | Journals | Submit | Contact Us | Français|
An overview of Personal Profiles can be found at http://www.moloncol.org.
Geneviève Almouzni received a PhD in Microbiology from the Université Pierre et Marie Curie, Paris, France, in 1988. After a postdoctoral visit at the National Institutes of Health, Bethesda, USA, in the laboratory of Alan P. Wolffe to deepen her expertise in chromatin studies, she established her own independent research on chromatin dynamics as a junior group leader holding a CNRS (Centre National de la Recherche Scientifique) position at the Institut Curie, Paris, France, in 1994. Further, she has been appointed as head of the Nuclear Dynamics and Genome Plasticity unit, a mixed structure between the Institut Curie and the CNRS in 1999. Since 2009, she has also taken the responsibility of Deputy Director in charge of advanced training for the Research center at the Institut Curie.
Her group over the years has conducted research on chromatin dynamics, histone variants, histone chaperones and nuclear organization with a particular interest on heterochromatin. Her general objective has been to dissect the mechanisms of chromatin assembly, from the basic structural unit, the nucleosome, up to the higher‐order structures in the nucleus. Her lab has characterized key chaperones involved in nucleosome assembly and defined the dynamics of new histone incorporation in chromatin. In addition, her work on specific nuclear domains has unveiled the importance of non‐coding centromeric heterochromatic regions, which are of major importance for chromosome segregation and relevant for cancer. These findings have shed light on the fundamental issues of the dynamics, fate, and inheritance of histones, with their specific marks typical of particular chromatin domains. In addition, her lab found that misregulation of specific histone chaperones is a common feature of aggressive breast cancers. Her lab has exploited a variety of tools and models to understand the in vivo functions of chromatin dynamics (e.g. Xenopus, mouse) that combine biochemistry, cell biology, and developmental biology. These integrated approaches from molecules to tissue and a whole organism are actively pursued.
In addition to her scientific work, she has participated in structuring research in Epigenetics in Europe to promote young scientists by her involvement in several networks, including the Epigenome European network (www.epigenome‐noe.net/WWW/index.php), and more recently, the network of excellence EpiGeneSys, to move epigenetics towards system biology (www.epigenesys.org) for which she acts as the scientific coordinator.
Dr. Almouzni serves on the Scientific Advisory Committees of numerous research organizations and is a member of several editorial boards in the fields of epigenetics, chromatin and development. She is the recipient of several awards for her contribution to the fields of epigenetics, chromatin and development including the CNRS Silver Medal (2003), the Ligue Contre le Cancer Prize (2003), the Cino et Simone del Duca Fondation Special Scientific Prize by the Institut de France (2006), the Louis D. Fondation Special Scientific Prize on Epigenetics by the Institut de France (2011) and the FEBS/EMBO Women in Science Award (2013). She has published more than 160 peer reviewed papers.
Professor Caldas holds the Chair of Cancer Medicine at the University of Cambridge since 2002. He is an Honorary Consultant Medical Oncologist at Addenbrooke's Hospital, Lead of the Cambridge Experimental Cancer Medicine Centre, Co‐Lead of the Cancer Theme at the NIHR Cambridge BRC and Director of the Cambridge Breast Cancer Research Unit. He heads the Breast Cancer Functional Genomics Laboratory at the Cancer Research UK Cambridge Institute. He is Fellow of the American College of Physicians, the Royal College of Physicians, the Royal College of Pathologists and the Society of Biology. He was elected a Fellow of the Academy of the Medical Sciences in 2004 and a Fellow of the European Academy of Cancer Sciences in 2010. He was selected as an NIHR Senior Investigator in 2012.
Professor Carlos Caldas is a graduate from the University of Lisbon Medical School and trained in Internal Medicine at UT Southwestern, Dallas and in Medical Oncology at Johns Hopkins Hospital, Baltimore. He then completed a research fellowship at the Institute of Cancer Research in London. In 1996 he moved to Cambridge where he has directed a research group working on the genetic alterations underlying human epithelial malignancies, with a particular focus on breast cancer.
His current research focus is in the functional genomics of breast cancer and its biological and clinical implications. He has also a research program on the genetics of gastric cancer. His main clinical interest is in breast cancer and novel molecularly targeted therapies. He has published over 200 peer‐reviewed papers including in Nature, Nature Genetics, Nature Medicine, Cell, Cancer Cell, Cell Reports, New England Journal of Medicine, Science Translational Medicine, PNAS, Cancer Research, Clinical Cancer Research, Journal of Clinical Oncology, Genome Biology, PLoS Biology, PLoS Medicine, Lancet Oncology, Journal of Pathology, Breast Cancer Research and Oncogene.
Manuel Hidalgo was born in Antequera, Malaga, in 1968. He received his MD from the Universidad de Navarra, Pamplona, in 1992 and his PhD from the Universidad Autonoma de Madrid in 1997.
Manuel specialised in Medical Oncology at the Hospital Universitario 12 de Octubre, Madrid, obtaining his license in 1996. He completed his training in drug development at the University of Texas Health Science Center, San Antonio (USA), where he briefly joined as Faculty. He then moved to Johns Hopkins University in 2001 as Co‐Director of the Drug Development and GI Programmes.
He joined the CNIO in 2009 to lead the GI Cancer Clinical Research Unit. Manuel is a founding member of the pancreatic cancer research team ‐ a clinical trials group focusing on novel therapeutics for pancreatic cancer. He has participated in the clinical development of more than 30 novel anticancer agents and led the early clinical trials with erlotinib and temsirolimus ‐ two recently approved drugs.
Manuel's work has contributed to the incorporation of molecular endpoints in early clinical trials. His group pioneered the utilisation of personalised xenograft models for drug screening, biomarker development and personalised cancer treatment.
He has published 180 papers in peer‐reviewed journals and his work has been funded by the NCI, AACR, and ASCO.
Manuel received an AACR Clinical Research Fellowship and an ASCO Career Development Award for his work on the development of EGFR inhibitors. His most recent efforts focus on novel therapeutics for pancreatic cancer.
In 2011, he was named Vice Director of Translational Research at CNIO charged with the mission to foster translational research at CNIO and with a broader implication of the Center in cancer care.
Marco A Pierotti
Marco A Pierotti is Scientific Director at the Fondazione IRCCS Istituto Nazionale Tumori of Milan since 2006. After graduating in Biological Sciences at the University of Milan, he was a Visiting Investigator at the Laboratory of Chemical Cancerogenesis NCI‐NIH Bethesda (USA) and Postdoctoral Research Fellow in the Laboratory of Viral Oncology at the Memorial Sloan‐Kettering Institute, New York (USA). In 1988 he became Director of the Department of Experimental Oncology and Laboratories at the Istituto Nazionale Tumori of Milan.
He is the Scientific Secretary of Alleanza Contro il Cancro, a member of ECCO's Policy Committee, the scientific director of the Lombardy Oncology Network (ROL), and a member of the central charity commission of the CARIPLO Foundation. Since 1988, he has been a Professor of Molecular Genetics of Tumors at the Postgraduate School of Oncology in the University of Milan Medical School. He is in the Board of the Organization of European Cancer Institutes (OECI), and is a member of the Advisory Board of Italian Association on Cancer Research (AIRC) and of the 2013–2015 AACR Laboratory Research Awards Committee. He contributed as an expert to various international review committee and collaborated among others with the Institute National du Cancer, the Research Council of Norway, the Swedish Research Council and the Canadian Institutes of Health Research. Dr. Pierotti's work has been recognized through a number of academic awards and honors including the ‘International Idea Award’ for Health in 2001 and the ‘Una vita per la ricerca’ ABO Project Award in 2008. Dr Pierotti is in the Editorial Board of Cancer Letters, Tumori, Genes Chromosomes Cancer, International Journal of Biological Markers, Molecular Cancer Research. He has published more than 460 publications including studies on immunology, biochemistry and molecular biology using both experimental and human tumors. His main scientific contributions are in the field of molecular biology of carcinogenesis, and in the study of thyroid cancer and is currently involved in various demanding research projects in early detection, tumor microenvironment and colorectal cancer control.
Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently the Head of the Medical Oncology Department at the Vall d'Hebron University Hospital in Barcelona and the Director of the Vall d'Hebron Institute of Oncology. He is very actively involved in translational research and pharmacodynamic phase I studies with molecular targeted therapies. He is especially devoted to phase I and II studies with pharmacodynamic endpoints with novel agents directed to the membrane receptors, like the EGFR‐family and IGF‐1R, the PI3K and ERK signalling pathways, as well as downstream cytoplasmatic and intranucleous effectors like Mdm2/p53 and aurora kinase. Based in the idea that each tumor has an independent genetic identity, the group he is leading very actively participates in the development of molecular therapies targeting specific oncoproteins, with the purpose of developing personalized therapies (e.g. against EGFR, HER2, BRAF, MEK, PI3K, Akt, mTOR or IGF1‐R among others) for those patients displaying genetic lesions or pathway disregulation. One of the main objectives of the group is to identify new predictive markers of response to diverse treatments and to identify markers of primary resistance (de novo) and secondary treatment. At a preclinical level, the group he is leading is developing new xenograft models with explant tumors from patients (“xenopatients”) in mice in order to mimic the patient's disease and study the tumor development in optimized research models. It also leads a program devoted to the study of circulating biomarkers (detection and genotyping of circulating free DNA).
In addition, Dr. Tabernero is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), and different Editorial Boards including the Journal of Clinical Oncology, Clinical Cancer Research, Cancer Discovery, Clinical Colorectal Cancer, The Oncologist and Annals of Oncology. He has (co)authored approximately 250 peer‐reviewed papers; 100 as first, second or senior author. He has also been member of the Educational and Scientific Committees of the ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and WCGIC (ESMO GI) meetings.
Professor Paul Workman is Deputy Chief Executive of The Institute of Cancer Research (ICR), London, Head of its Division of Cancer Therapeutics and Harrap Professor of Pharmacology and Therapeutics. Paul is also Director of Cancer Research UK Cancer Therapeutics Unit at ICR – the largest non‐profit cancer drug discovery group in the world.
Paul is a pioneer in the discovery of molecular targeted therapies. He is especially renowned for his innovative personal research in the discovery, chemical biology and molecular pharmacology of HSP90 and PI3 kinase inhibitors and as the originator of the widely used Pharmacologic Audit Trail for biomarker‐led drug development. Paul has also been the founder of two biotechnology companies, Piramed Pharma and Chroma Therapeutics.
Since 2005, under Paul's leadership the Cancer Therapeutics Unit has discovered 16 drug candidates, including inhibitors of the molecular chaperone HSP90, PI3 kinase and PKB/AKT. Six of the Unit's drugs are currently undergoing Phase I/II clinical trials and abiraterone was approved in 2012 for late‐stage prostate cancer. Paul has published over 470 research publications and has received numerous honours and awards. He has been elected as a Fellow of the Academy of Medical Sciences and was the leader of the ICR/Royal Marsden Hospital Team that won the prestigious American Association for Cancer Research Team Science Award in 2012. He also received the 2012 Royal Society of Chemistry World Entrepreneur Award and the 2010 Royal Society of Chemistry George and Christine Sosnovsky Award in Cancer Therapy.
Pedersen Dorte Holst, (2013), New members of the editorial board — Personal profiles, Molecular Oncology, 7, doi: 10.1016/j.molonc.2013.07.004.